Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study
口服利扎替尼(首个用于治疗寻常型天疱疮的布鲁顿酪氨酸激酶抑制剂)临床疗效的概念验证:II期BELIEVE研究
期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1111/bjd.20431
Murrell, D F; Patsatsi, A; Stavropoulos, P; Baum, S; Zeeli, T; Kern, J S; Roussaki-Schulze, A-V; Sinclair, R; Bassukas, I D; Thomas, D; Neale, A; Arora, P; Caux, F; Werth, V P; Gourlay, S G; Joly, P